Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human Biglycan Anticorps:
anti-Mouse (Murine) Biglycan Anticorps:
anti-Rat (Rattus) Biglycan Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal Biglycan Primary Antibody pour IHC, ELISA - ABIN188683
Antipova, Orgel: Non-enzymatic decomposition of collagen fibers by a biglycan antibody and a plausible mechanism for rheumatoid arthritis. dans PLoS ONE 2012
Show all 4 Pubmed References
Human Polyclonal Biglycan Primary Antibody pour IF (p), IHC (p) - ABIN872817
Huang, Zou, Shi, Zhang, Pen, Zhang, Gao, Wang: The effect of electroacupuncture on the extracellular matrix synthesis and degradation in a rabbit model of disc degeneration. dans Evidence-based complementary and alternative medicine : eCAM 2014
Show all 2 Pubmed References
Human Polyclonal Biglycan Primary Antibody pour IHC, IHC (p) - ABIN4284625
Van Bockstal, Lambein, Van Gele, De Vlieghere, Limame, Braems, Van den Broecke, Cocquyt, Denys, Bracke, Libbrecht, De Wever: Differential regulation of extracellular matrix protein expression in carcinoma-associated fibroblasts by TGF-β1 regulates cancer cell spreading but not adhesion. dans Oncoscience 2015
Show all 2 Pubmed References
Human Polyclonal Biglycan Primary Antibody pour WB - ABIN513714
Gasimli, Stansfield, Nairn, Liu, Paluh, Yang, Dordick, Moremen, Linhardt: Structural remodeling of proteoglycans upon retinoic acid-induced differentiation of NCCIT cells. dans Glycoconjugate journal 2013
Human Monoclonal Biglycan Primary Antibody pour IHC (p), IP - ABIN560056
Zhang, Lee, Young, Wang: The Small Leucine-Rich Proteoglycan BGN Accumulates in CADASIL and Binds to NOTCH3. dans Translational stroke research 2015
Rat (Rattus) Polyclonal Biglycan Primary Antibody pour ELISA, WB - ABIN334359
Chen, Lenschow, Tiede, Fischer, Kalthoff, Ungefroren: Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. dans The Journal of biological chemistry 2002
Show all 2 Pubmed References
The differential immunoexpression of perlecan (Montrer HSPG2 Anticorps) and biglycan in these types of ameloblastomas suggests their participation in the developmental process of these tumors.
TLR2 and BGN contribute to sterile inflammation and infertility in man.
Results show that Biglycan expression was upregulated by DNA demethylation in tumour endothelial cells from myeloma.
Elevated biglycan mRNA expression in adipose tissues of obese women
sex-specific allele combinations of BGN, COL5A1 (Montrer COL5A1 Anticorps), and DCN (Montrer DCN Anticorps), as well as eight miRNA recognition sequences, were associated with altered susceptibility to anterior cruciate ligament ruptures
high Bgn expression levels promote a more dense collagen architecture, leading to increased tissue stiffness. This increased tissue stiffness leads to higher integrin-beta1 expression on melanoma cells, which promotes their invasiveness.
The expression of hBGN in the skeletal muscle of the treated mice was 1.34-fold higher than that of the native mouse Bgn (mBgn). The low transduction efficiency and improved motor functions suggest that biglycan expressed in a small number of muscle fibers was likely to have been secreted and anchored to the cell surface throughout the whole muscular fibers
Results identified loss-of-function mutation in BGN gene in patients with an X-linked syndromic form of severe thoracic aortic aneurysms and dissections (TAAD) confirming BGN as causative gene in severe form of TAAD.
After the first year of smoking abstinence the levels of BGN expression and carotid-femoral pulse wave velocity are significantly improved as compared to baseline.
study reports a temporal relationship between altered placental biglycan expression and subsequent development of fetal growth restriction/small for gestational age.
Knockout results provide evidence that decorin (Montrer DCN Anticorps) and biglycan are necessary for maintaining collagen fibril structure, fiber realignment, and mechanical properties of mature tendons.
A novel biological pathway has been discovered of soluble biglycan inducing HIF-2alpha (Montrer EPAS1 Anticorps) protein stabilization and Epo (Montrer EPO Anticorps) production presumably in an oxygen-independent manner, ultimately giving rise to secondary polycythemia.
Results show that Bgn plays a role in the process of angiogenesis during fracture healing, and that effect appears to be partially mediated through endostatin (Montrer COL18A1 Anticorps) suppression.
Asporin (Montrer ASPN Anticorps) deficiency changes skin glycosaminoglycan composition, and decorin (Montrer DCN Anticorps) and biglycan content, which may explain the changes in skin mechanical properties.
Biglycan plays a protective role during the progression of atherosclerosis in ApoE (Montrer APOE Anticorps)-deficient mice by inhibiting thrombin (Montrer F2 Anticorps) generation.
These genes were concordantly induced by TAC (Montrer IL2RA Anticorps) in WT but not in biglycan KO mice. CONCLUSIONS: Left ventricular pressure overload induces biglycan expression in cardiac fibroblasts. Ablation of biglycan improves cardiac function and attenuates left ventricular hypertrophy and fibrosis after long-term pressure overload.
Importance of biglycan and decorin (Montrer DCN Anticorps) as targets for the manipulation of fetal membrane extracellular matrix stability in the context of inflammation.
Biglycan deficiency leads to loosely packed aortic collagen fibers, increased susceptibility of aortic elastin (Montrer ELN Anticorps) fibers to angII-induced stress, and up-regulation of vascular perlecan (Montrer HSPG2 Anticorps) content.
Biglycan signaling supported fetal membrane remodeling during early gestation in the absence of concomitant changes in TGFbeta (Montrer TGFB1 Anticorps) levels.
Lumican (Montrer LUM Anticorps) and biglycan influence corneal keratocyte lamellipodia organization and are critical in the regulation of stromal collagen fibrillogenesis.
Data show that biglycan, collagen type I, collagen type II, decorin (Montrer DCN Anticorps), and versican (Montrer Vcan Anticorps) were significantly affected by vibration duration, frequency, and amplitude.
biglycan showed a unique ability to organize collagen VI into extensive hexagonal-like networks over a time period of only a few minutes
biglycan-induced fibroblast cytoskeletal and signalling changes result in an increased cell migration; potential role in the remodelling process
The results indicate that CTGF (Montrer CTGF Anticorps) suppresses the synthesis of biglycan but newly induced that of decorin (Montrer DCN Anticorps) in the cells when the cell density is low.
LDL electrostatic interactions with decorin (Montrer DCN Anticorps) and biglycan in the aortic valve leaflets and vascular wall is a major source of LDL retention.
Bgn regulates BMP4 (Montrer BMP4 Anticorps) signaling through modulation of Chordin (Montrer CHRD Anticorps) anti-BMP4 (Montrer BMP4 Anticorps) activity.
The protein encoded by this gene is a small cellular or pericellular matrix proteoglycan that is closely related in structure to two other small proteoglycans, decorin and fibromodulin. The encoded protein and decorin are thought to be the result of a gene duplication. Decorin contains one attached glycosaminoglycan chain, while this protein probably contains two chains. For this reason, this protein is called biglycan. This protein plays a role in assembly of collagen fibrils and muscle regeneration. It interacts with several proteins involved in muscular dystrophy, including alpha-dystroglycan, alpha- and gamma-sarcoglycan and collagen VI, and it is critical for the assembly of the dystrophin-associated protein complex.
, bone/cartilage proteoglycan I
, bone/cartilage proteoglycan-I
, dermatan sulphate proteoglycan I
, small leucine-rich protein 1A
, Small proteoglycan I (biglycan), bone (BSPG1) (bone/cartilage proteclycan 1 precursor)
, bone/cartilage proteclycan 1
, leucine-rich PG I